48-year-old woman with recurrent ductal carcinoma in situ (DCIS) in left breast

 

48-year-old woman with recurrent ductal carcinoma in situ (DCIS) in left breast. A. Mammographic magnification view shows grouped calcifications in left breast (circle). Stereotactic biopsy yielded grade 2 DCIS. Patient underwent lumpectomy with tumor-negative surgical margins and radiation therapy. B. Mammographic magnification view obtained 4 years after diagnosis shows new calcifications at surgical site (circle). Stereotactic biopsy was performed, which revealed recurrent grade 2 DCIS. Patient then underwent mastectomy.


December 26, 2023 — Results published in the American Journal of Roentgenology (AJR) support mammographic surveillance protocol for patients with a previous breast cancer diagnosis of returning immediately to digital breast tomosynthesis (DBT) screening.

“Although the abnormal interpretation rate (AIR) was higher during the year after diagnosis compared to subsequent years, the AIR remained acceptably low (< 10%) in all years,” concluded lead investigator Dan Do, BA, from Massachusetts General Hospital in Boston.  

This AJR accepted manuscript included 8,090 patients (mean age, 65 years) with a prior breast cancer diagnosis who underwent 30,812 screening DBT examinations during Do et al.’s study period. The cancer detection rate (CDR) was 8.6 per 1,000 examinations, AIR was 5.7%, PPV 1 was 15.1%, sensitivity was 80.3%, specificity was 95.1%, and false-negative rate was 2.1%.

Ultimately, CDR showed a significant independent positive association with years since breast cancer diagnosis (adjusted OR 1.03, 95% CI 1.01-1.05, p<.001). Meanwhile, AIR evidenced significant independent negative association with years since breast cancer diagnosis (adjusted OR 0.99, 95% CI 0.98-1.00, p=.01)—being highest less than or equal to 1 year after diagnosis (7.5%) and lowest greater than 5, but less than 6 years postdiagnosis (5.0%).

For more information: www.arrs.org


Related Content

News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
News | FDA

Dec. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT, has announced ...

Time December 04, 2025
arrow
News | Women's Health

Dec. 1, 2025 — ScreenPoint Medical has completed a commercial agreement making its Transpara breast-imaging AI portfolio ...

Time December 03, 2025
arrow
News | Mammography

Nov. 30, 2025 — At RSNA 2025, Siemens Healthineers will introduce new capabilities for its Mammomat B.brilliant ...

Time December 02, 2025
arrow
News | RSNA 2025

Dec. 2, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, will present 14 studies at RSNA ...

Time December 02, 2025
arrow
News | Women's Health

Dec. 1, 2025 — A study of data from seven outpatient facilities in the New York region found that 20-24% of all the ...

Time December 02, 2025
arrow
News | Mammography

Nov. 26, 2025 — GE HealthCare has announced it received FDA Premarket Authorization for Pristina Recon DL, an advanced ...

Time November 29, 2025
arrow
News | Artificial Intelligence

Nov. 25, 2025 – Medical imaging AI company Avicenna.AI has announced a strategic partnership with Ferrum, an AI ...

Time November 25, 2025
arrow
News | Ultrasound Imaging

Nov. 12, 2025 — GE HealthCare and DeepHealth, Inc., a wholly owned subsidiary of RadNet, Inc., have announced their ...

Time November 20, 2025
arrow
News | Breast Imaging

Nov. 17, 2025 — RadNet, Inc. and its wholly owned subsidiary, DeepHealth have announced results from the largest real ...

Time November 17, 2025
arrow
Subscribe Now